secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001104659-23-102807
Event type: litigation
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome discloses merger-related lawsuits and supplemental proxy disclosures
-----------------------------------------------------------------------------

- Two securities lawsuits filed by purported stockholders challenging the merger: Weiss v. Immunome (Sept 7) and Thompson v. Immunome (Sept 8).
- Eleven stockholder demands and one books-and-records demand received regarding disclosure adequacy in the merger proxy.
- Immunome denies wrongdoing but issues supplemental disclosures to avoid litigation costs and potential disruption to the merger.
- Disclosures include details on the Transaction Committee, background discussions, discounted cash flow analysis ranges, and Dr. Siegall's recruitment.
- Exchange ratio implies Immunome stockholders would own ~55% of the combined company on a fully diluted basis before PIPE and option grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923102807/0001104659-23-102807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923102807/tm2326649d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-102807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer